Impact of Gene Polymorphism on Platelet Reactivity and Clinical Outcomes During Dual Antiplatelet Therapy With Aspirin and Clopidogrel in Coronary Heart Disease

Impact of Gene Polymorphism on Platelet Reactivity and Clinical Outcomes During Dual Antiplatelet Therapy With Aspirin and Clopidogrel in Coronary Heart Disease - Gene Polymorphism During Dual Antiplatelet Therapy

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000012682

Enrollment

500

Registered

2013-12-25

Start date

2013-12-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary artery disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: We firstly registered patients who underwent PCI in Kumamoto University Hospital, and enrolled patients with dual antiplatelet therapy including aspirin and clopidogrel

Exclusion criteria

Exclusion criteria: 1.known allergy to aspirin or clopidogrel 2. thrombocytopenia 3. severe liver dysfunction 4. malignant disease with severe prognosis 5. patients taking other antithrombotic agents

Design outcomes

Primary

Measure	Time frame
Residual platelet reactivity and cardiovascular event	—

Countries

Japan

Contacts

Public ContactSeiji Hokimoto

Graduate School of Medical Sciences, Kumamoto University Department of Cardiovascular Medicine

shokimot@kumamoto-u.ac.jp096-373-5175

Outcome results